[Antiaggregation activity of arachidonic acid conjugates with neurotropic peptides proglyprol and semax].

Bezuglov VV, Gretskaia NM, Vasil'eva TM, Petrukhina GN, Andreeva LA, Miasoedov NF, Makarov VA

Eksperimental'naia i klinicheskaia farmakologiia1 Jan 2014

PMID25102733PepBankPUB-25102733

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semax.

01LabNot a test of Semax aloneIn vitro (cells)Activity measurement
In vitro, arachidonic acid conjugates of semax and proglyprol produced a moderate dose-dependent decrease in ADP-induced platelet interaction at 0.018-1.8 mM.
In plain wordsIn lab tests, semax joined to arachidonic acid reduced platelets clumping after ADP, unlike the unmodified peptide.
Peptide
Semax
Outcome
DecreaseADP-induced platelet aggregation
Study
n: not reported in source
Platelet aggregation in vitro
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
Concentration range tested
0.018 to 1.8 mM
arachidonic acid conjugates
Source sentences
Summary
It is established that both derivatives, in contrast to the parent peptide, possess moderate anti-aggregant properties and produce a dose-dependent decrease in the interplatelet interaction induced by ADP, epinephrine, and arachidonic acid within the concentration range of 0.018 - 1.8 mM.
1 context sentence(design, population, supporting numbers)
Summary · context
The influence two original derivatives of a therapeutically important peptide, bearing arachidonic acid residue with semax and proglyprol, upon platelet aggregation have been studied in vitro.
In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.
Report a problemFND-2510273301
02LabNot a test of Semax aloneIn vitro (cells)Activity measurement
In vitro, arachidonic acid conjugates of semax and proglyprol produced a moderate dose-dependent decrease in epinephrine-induced platelet interaction at 0.018-1.8 mM.
In plain wordsIn lab tests, semax joined to arachidonic acid reduced platelets clumping after epinephrine, unlike the unmodified peptide.
Peptide
Semax
Outcome
DecreaseEpinephrine-induced platelet aggregation
Study
n: not reported in source
Platelet aggregation in vitro
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
Concentration range tested
0.018 to 1.8 mM
arachidonic acid conjugates
Source sentences
Summary
It is established that both derivatives, in contrast to the parent peptide, possess moderate anti-aggregant properties and produce a dose-dependent decrease in the interplatelet interaction induced by ADP, epinephrine, and arachidonic acid within the concentration range of 0.018 - 1.8 mM.
1 context sentence(design, population, supporting numbers)
Summary · context
The influence two original derivatives of a therapeutically important peptide, bearing arachidonic acid residue with semax and proglyprol, upon platelet aggregation have been studied in vitro.
In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.
Report a problemFND-2510273302
03LabNot a test of Semax aloneIn vitro (cells)Activity measurement
In vitro, arachidonic acid conjugates of semax and proglyprol produced a moderate dose-dependent decrease in arachidonic acid-induced platelet interaction at 0.018-1.8 mM.
In plain wordsIn lab tests, semax joined to arachidonic acid reduced platelets clumping after arachidonic acid, unlike the unmodified peptide.
Peptide
Semax
Outcome
DecreaseArachidonic acid-induced platelet aggregation
Study
n: not reported in source
Platelet aggregation in vitro
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
Concentration range tested
0.018 to 1.8 mM
arachidonic acid conjugates
Source sentences
Summary
It is established that both derivatives, in contrast to the parent peptide, possess moderate anti-aggregant properties and produce a dose-dependent decrease in the interplatelet interaction induced by ADP, epinephrine, and arachidonic acid within the concentration range of 0.018 - 1.8 mM.
1 context sentence(design, population, supporting numbers)
Summary · context
The influence two original derivatives of a therapeutically important peptide, bearing arachidonic acid residue with semax and proglyprol, upon platelet aggregation have been studied in vitro.
In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.
Report a problemFND-2510273303
04LabNot a test of Semax aloneIn vitro (cells)Activity measurement
In vitro, the anti-aggregant activity of arachidonoylsemax was more pronounced than that of arachidonoylproglyprol.
In plain wordsIn lab tests, semax joined to arachidonic acid reduced platelet clumping more than proglyprol joined to arachidonic acid.
Peptide
Semax
Outcome
DecreaseAnti-aggregant activity, arachidonoylsemax versus arachidonoylproglyprol
Study
n: not reported in source
Platelet aggregation in vitro
Comparator
Arachidonoylproglyprol
Outcome group
Bleeding and clotting · Cardiovascular
Source sentences
Summary
This activity was more pronounced for arachidonoylsemax in comparison with arachidonoylproglyprol.
1 context sentence(design, population, supporting numbers)
Summary · context
The influence two original derivatives of a therapeutically important peptide, bearing arachidonic acid residue with semax and proglyprol, upon platelet aggregation have been studied in vitro.
In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.
Report a problemFND-2510273304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.